Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 11;26(1):78–88. doi: 10.1080/10717544.2018.1556361

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — (A–C) The qRT-PCR assay showed that the mRNA levels of Caspase-3, CHOP, and Bax in the INas administered group were significantly down-regulated compared with the MNU group. The mRNA level of Caspase-3, CHOP, and Bax in the INas administered group was also significantly lower than that in the IVen administered group. (D) In the INas administered group, the mRNA level of Bcl-2 was significantly higher compared with the MNU group, suggesting that the anti-apoptotic mechanism should be responsible for the EPO mediated protection. (E) The retinal MDA concentration in the INas administered group was significantly lower than that in the MNU group. (F) The expression level of SOD in the INas administered group was significantly up-regulated compared with the MNU group, suggesting that the INas delivery of EPO could alter the oxidation status in the degenerative retina. (G) The Mn-SOD level in the IVen administered group was significantly higher than that in the MNU group. Meanwhile, the Mn-SOD level in the IVen administered group was significantly lower than that in the INas administered group (ANOVA analysis followed by Bonferroni's post-hoc analysis was performed,*p < .05, #p < .01, for differences between groups; n = 10).